Pharma, Non-Profits Ally To Advance TB Drug Combinations
Goal Is Shorter Duration Treatment Regimens
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.
You may also be interested in...
Results from a Phase II trial have demonstrated the potential of GSK's first-in-class antitubercular agent to be a component of simpler treatment regimens for tuberculosis in the future.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
The Medicines Patent Pool, a UN-backed public health organization, has announced deals with two major global pharma firms aimed at providing innovative, effective and affordable treatment for people - including children - living with HIV and TB.